Ligand Pharmaceuticals Q3 Adj. EPS $2.67 Beats $2.38 Estimate, Sales $78.700M Beat $77.232M Estimate
Benzinga Newsdesk 2 days ago
NewsEarningsEarnings Beats
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $2.67 per share which beat the analyst consensus estimate of $2.38 by 12.18 percent. This is a 13.59 percent decrease over earnings of $3.09 per share
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $2.67 per share which beat the analyst consensus estimate of $2.38 by 12.18 percent. This is a 13.59 percent decrease over earnings of $3.09 per share from the same period last year. The company reported quarterly sales of $78.700 million which beat the analyst consensus estimate of $77.232 million by 1.90 percent. This is a 31.84 percent decrease over sales of $115.461 million the same period last year.